US Tech 100

18,108.00

0.16%

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

AB

Ab Science (AB)

Ab Science

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:EU:AB

1 2 3 4 5 6 7 8 9 10 Next >>

Date	Time	Source	Headline	Symbol	Company
05/15/2024	2:16PM	GlobeNewswire Inc.	AB Science reports its revenues for the year 2023 and provides an update on its activities	EU:AB	Ab Science
05/15/2024	2:16PM	GlobeNewswire Inc.	AB Science annonce ses résultats financiers annuels arrêtés au 31 décembre 2023 et présente un point sur ses activités	EU:AB	Ab Science
05/15/2024	2:16PM	GlobeNewswire Inc.	AB Science reports its revenues for the year 2023 and provides an update on its activities	EU:AB	Ab Science
05/13/2024	12:08PM	GlobeNewswire Inc.	AB Science annonce la délivrance d’un brevet européen pour le masitinib dans le traitement de la mastocytose sévère avec une protection jusqu’en 2036	EU:AB	Ab Science
05/13/2024	12:08PM	GlobeNewswire Inc.	AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036	EU:AB	Ab Science
05/13/2024	12:08PM	GlobeNewswire Inc.	AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036	EU:AB	Ab Science
05/07/2024	12:05PM	GlobeNewswire Inc.	AB Science:	EU:AB	Ab Science
05/07/2024	12:05PM	GlobeNewswire Inc.	AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient	EU:AB	Ab Science
05/07/2024	12:05PM	GlobeNewswire Inc.	AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient	EU:AB	Ab Science
05/02/2024	1:14PM	GlobeNewswire Inc.	AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science	EU:AB	Ab Science
05/02/2024	1:14PM	GlobeNewswire Inc.	AB Science : La Cour d’Appel de Paris confirme la mise hors de cause du Président Directeur Général d’AB Science, Alain Moussy, et diminue le montant de la sanction imposée à AB Science	EU:AB	Ab Science
05/02/2024	1:14PM	GlobeNewswire Inc.	AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science	EU:AB	Ab Science
04/30/2024	12:56PM	GlobeNewswire Inc.	AB Science announces a slight delay in the publication of its 2023 annual financial report	EU:AB	Ab Science
04/30/2024	12:56PM	GlobeNewswire Inc.	AB Science annonce un léger décalage de la publication de son rapport financier annuel 2023	EU:AB	Ab Science
04/30/2024	12:56PM	GlobeNewswire Inc.	AB Science announces a slight delay in the publication of its 2023 annual financial report	EU:AB	Ab Science
04/03/2024	12:08PM	GlobeNewswire Inc.	AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS	EU:AB	Ab Science
04/03/2024	12:08PM	GlobeNewswire Inc.	AB Science annonce que Santé Canada a jugé admissible la demande de réexamen du masitinib dans SLA	EU:AB	Ab Science
03/13/2024	7:58AM	GlobeNewswire Inc.	AB Science : De nouvelles recherches montrent que le masitinib limite les dommages neuronaux dans un modèle de maladie neurodégénérative d’origine neuroimmune	EU:AB	Ab Science
03/13/2024	7:58AM	GlobeNewswire Inc.	AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease	EU:AB	Ab Science
03/13/2024	7:58AM	GlobeNewswire Inc.	AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease	EU:AB	Ab Science
03/07/2024	9:20AM	GlobeNewswire Inc.	AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development	EU:AB	Ab Science
03/07/2024	9:20AM	GlobeNewswire Inc.	AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development	EU:AB	Ab Science
03/07/2024	9:20AM	GlobeNewswire Inc.	AB Science propose un résumé de la conférence virtuelle qui s’est tenue le 4 mars 2024, avec pour objectif de faire le point sur le développement d'AB Science	EU:AB	Ab Science
03/06/2024	2:21PM	GlobeNewswire Inc.	AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company	EU:AB	Ab Science
03/06/2024	2:21PM	GlobeNewswire Inc.	AB Science annonce l’initiation de la couverture de son titre par deux sociétés d’analyse financières, DNA Finance d’une part, et par In Extenso Finance d’autre part	EU:AB	Ab Science
03/06/2024	2:21PM	GlobeNewswire Inc.	AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company	EU:AB	Ab Science
03/01/2024	12:07PM	GlobeNewswire Inc.	AB Science tiendra une conférence virtuelle le lundi 4 mars 2024, de 18h30 à 19h30	EU:AB	Ab Science
03/01/2024	12:07PM	GlobeNewswire Inc.	AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET	EU:AB	Ab Science
03/01/2024	12:07PM	GlobeNewswire Inc.	AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET	EU:AB	Ab Science
02/29/2024	5:49AM	GlobeNewswire Inc.	AB Science tiendra une conférence virtuelle le lundi 4 mars 2024, de 18h30 à 19h30	EU:AB	Ab Science